Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
27,461
archived clinical trials in
Hematology

Histone Deacetylase Inhibitor LBH589 in Addition to Corticosteroids in Patients With Acute Graft Versus Host Disease (GVHD)
A Phase I/II Trial Evaluating the Use of Histone Deacetylase Inhibitor LBH589 in Addition to Corticosteroids in Patients With Acute Graft Versus Host Disease
Status: Enrolling
Updated:  12/31/1969
823
mi
from 43215
Tampa, FL
Histone Deacetylase Inhibitor LBH589 in Addition to Corticosteroids in Patients With Acute Graft Versus Host Disease (GVHD)
A Phase I/II Trial Evaluating the Use of Histone Deacetylase Inhibitor LBH589 in Addition to Corticosteroids in Patients With Acute Graft Versus Host Disease
Status: Enrolling
Updated: 12/31/1969
H. Lee Moffitt Cancer Center & Research Institute
823
mi
from 43215
Tampa, FL
Click here to add this to my saved trials
Eltrombopag in Elderly Acute Myelogenous Leukemia (AML)
A Phase I/II Study of Eltrombopag in Elderly Patients With AML
Status: Enrolling
Updated:  12/31/1969
414
mi
from 43215
Philadelphia, PA
Eltrombopag in Elderly Acute Myelogenous Leukemia (AML)
A Phase I/II Study of Eltrombopag in Elderly Patients With AML
Status: Enrolling
Updated: 12/31/1969
Abramson Cancer Center of the University of Pennsylvania
414
mi
from 43215
Philadelphia, PA
Click here to add this to my saved trials
Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell Transplant (PBSC) in Hodgkin, Non-Hodgkin Lymphoma or Multiple Myeloma Patients
Phase II Study Evaluating the Safety and Efficacy of TXA127 in the Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell Transplant in Patients With Hodgkin Lymphoma, Non-Hodgkin Lymphoma or Multiple Myeloma Undergoing Limited Reinfusion of CD34+ Cells
Status: Enrolling
Updated:  12/31/1969
1955
mi
from 43215
Duarte, CA
Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell Transplant (PBSC) in Hodgkin, Non-Hodgkin Lymphoma or Multiple Myeloma Patients
Phase II Study Evaluating the Safety and Efficacy of TXA127 in the Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell Transplant in Patients With Hodgkin Lymphoma, Non-Hodgkin Lymphoma or Multiple Myeloma Undergoing Limited Reinfusion of CD34+ Cells
Status: Enrolling
Updated: 12/31/1969
City of Hope Hospital
1955
mi
from 43215
Duarte, CA
Click here to add this to my saved trials
Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell Transplant (PBSC) in Hodgkin, Non-Hodgkin Lymphoma or Multiple Myeloma Patients
Phase II Study Evaluating the Safety and Efficacy of TXA127 in the Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell Transplant in Patients With Hodgkin Lymphoma, Non-Hodgkin Lymphoma or Multiple Myeloma Undergoing Limited Reinfusion of CD34+ Cells
Status: Enrolling
Updated:  12/31/1969
435
mi
from 43215
Atlanta, GA
Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell Transplant (PBSC) in Hodgkin, Non-Hodgkin Lymphoma or Multiple Myeloma Patients
Phase II Study Evaluating the Safety and Efficacy of TXA127 in the Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell Transplant in Patients With Hodgkin Lymphoma, Non-Hodgkin Lymphoma or Multiple Myeloma Undergoing Limited Reinfusion of CD34+ Cells
Status: Enrolling
Updated: 12/31/1969
Emory University
435
mi
from 43215
Atlanta, GA
Click here to add this to my saved trials
Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell Transplant (PBSC) in Hodgkin, Non-Hodgkin Lymphoma or Multiple Myeloma Patients
Phase II Study Evaluating the Safety and Efficacy of TXA127 in the Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell Transplant in Patients With Hodgkin Lymphoma, Non-Hodgkin Lymphoma or Multiple Myeloma Undergoing Limited Reinfusion of CD34+ Cells
Status: Enrolling
Updated:  12/31/1969
277
mi
from 43215
Chicago, IL
Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell Transplant (PBSC) in Hodgkin, Non-Hodgkin Lymphoma or Multiple Myeloma Patients
Phase II Study Evaluating the Safety and Efficacy of TXA127 in the Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell Transplant in Patients With Hodgkin Lymphoma, Non-Hodgkin Lymphoma or Multiple Myeloma Undergoing Limited Reinfusion of CD34+ Cells
Status: Enrolling
Updated: 12/31/1969
Rush University Medical Center
277
mi
from 43215
Chicago, IL
Click here to add this to my saved trials
Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell Transplant (PBSC) in Hodgkin, Non-Hodgkin Lymphoma or Multiple Myeloma Patients
Phase II Study Evaluating the Safety and Efficacy of TXA127 in the Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell Transplant in Patients With Hodgkin Lymphoma, Non-Hodgkin Lymphoma or Multiple Myeloma Undergoing Limited Reinfusion of CD34+ Cells
Status: Enrolling
Updated:  12/31/1969
166
mi
from 43215
Indianapolis, IN
Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell Transplant (PBSC) in Hodgkin, Non-Hodgkin Lymphoma or Multiple Myeloma Patients
Phase II Study Evaluating the Safety and Efficacy of TXA127 in the Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell Transplant in Patients With Hodgkin Lymphoma, Non-Hodgkin Lymphoma or Multiple Myeloma Undergoing Limited Reinfusion of CD34+ Cells
Status: Enrolling
Updated: 12/31/1969
IU Simon Cancer Center
166
mi
from 43215
Indianapolis, IN
Click here to add this to my saved trials
Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell Transplant (PBSC) in Hodgkin, Non-Hodgkin Lymphoma or Multiple Myeloma Patients
Phase II Study Evaluating the Safety and Efficacy of TXA127 in the Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell Transplant in Patients With Hodgkin Lymphoma, Non-Hodgkin Lymphoma or Multiple Myeloma Undergoing Limited Reinfusion of CD34+ Cells
Status: Enrolling
Updated:  12/31/1969
682
mi
from 43215
Omaha, NE
Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell Transplant (PBSC) in Hodgkin, Non-Hodgkin Lymphoma or Multiple Myeloma Patients
Phase II Study Evaluating the Safety and Efficacy of TXA127 in the Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell Transplant in Patients With Hodgkin Lymphoma, Non-Hodgkin Lymphoma or Multiple Myeloma Undergoing Limited Reinfusion of CD34+ Cells
Status: Enrolling
Updated: 12/31/1969
Univ of Nebraska Med Ctr
682
mi
from 43215
Omaha, NE
Click here to add this to my saved trials
Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell Transplant (PBSC) in Hodgkin, Non-Hodgkin Lymphoma or Multiple Myeloma Patients
Phase II Study Evaluating the Safety and Efficacy of TXA127 in the Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell Transplant in Patients With Hodgkin Lymphoma, Non-Hodgkin Lymphoma or Multiple Myeloma Undergoing Limited Reinfusion of CD34+ Cells
Status: Enrolling
Updated:  12/31/1969
275
mi
from 43215
Charlottesville, VA
Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell Transplant (PBSC) in Hodgkin, Non-Hodgkin Lymphoma or Multiple Myeloma Patients
Phase II Study Evaluating the Safety and Efficacy of TXA127 in the Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell Transplant in Patients With Hodgkin Lymphoma, Non-Hodgkin Lymphoma or Multiple Myeloma Undergoing Limited Reinfusion of CD34+ Cells
Status: Enrolling
Updated: 12/31/1969
University of Virginia Health System
275
mi
from 43215
Charlottesville, VA
Click here to add this to my saved trials
Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell Transplant (PBSC) in Hodgkin, Non-Hodgkin Lymphoma or Multiple Myeloma Patients
Phase II Study Evaluating the Safety and Efficacy of TXA127 in the Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell Transplant in Patients With Hodgkin Lymphoma, Non-Hodgkin Lymphoma or Multiple Myeloma Undergoing Limited Reinfusion of CD34+ Cells
Status: Enrolling
Updated:  12/31/1969
398
mi
from 43215
Saint Louis, MO
Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell Transplant (PBSC) in Hodgkin, Non-Hodgkin Lymphoma or Multiple Myeloma Patients
Phase II Study Evaluating the Safety and Efficacy of TXA127 in the Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell Transplant in Patients With Hodgkin Lymphoma, Non-Hodgkin Lymphoma or Multiple Myeloma Undergoing Limited Reinfusion of CD34+ Cells
Status: Enrolling
Updated: 12/31/1969
Washington University
398
mi
from 43215
Saint Louis, MO
Click here to add this to my saved trials
Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell Transplant (PBSC) in Hodgkin, Non-Hodgkin Lymphoma or Multiple Myeloma Patients
Phase II Study Evaluating the Safety and Efficacy of TXA127 in the Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell Transplant in Patients With Hodgkin Lymphoma, Non-Hodgkin Lymphoma or Multiple Myeloma Undergoing Limited Reinfusion of CD34+ Cells
Status: Enrolling
Updated:  12/31/1969
523
mi
from 43215
Long Island City, NY
Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell Transplant (PBSC) in Hodgkin, Non-Hodgkin Lymphoma or Multiple Myeloma Patients
Phase II Study Evaluating the Safety and Efficacy of TXA127 in the Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell Transplant in Patients With Hodgkin Lymphoma, Non-Hodgkin Lymphoma or Multiple Myeloma Undergoing Limited Reinfusion of CD34+ Cells
Status: Enrolling
Updated: 12/31/1969
Stony Brook
523
mi
from 43215
Long Island City, NY
Click here to add this to my saved trials
Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell Transplant (PBSC) in Hodgkin, Non-Hodgkin Lymphoma or Multiple Myeloma Patients
Phase II Study Evaluating the Safety and Efficacy of TXA127 in the Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell Transplant in Patients With Hodgkin Lymphoma, Non-Hodgkin Lymphoma or Multiple Myeloma Undergoing Limited Reinfusion of CD34+ Cells
Status: Enrolling
Updated:  12/31/1969
1511
mi
from 43215
Salt Lake City, UT
Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell Transplant (PBSC) in Hodgkin, Non-Hodgkin Lymphoma or Multiple Myeloma Patients
Phase II Study Evaluating the Safety and Efficacy of TXA127 in the Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell Transplant in Patients With Hodgkin Lymphoma, Non-Hodgkin Lymphoma or Multiple Myeloma Undergoing Limited Reinfusion of CD34+ Cells
Status: Enrolling
Updated: 12/31/1969
Huntsman Cancer Institute
1511
mi
from 43215
Salt Lake City, UT
Click here to add this to my saved trials
Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell Transplant (PBSC) in Hodgkin, Non-Hodgkin Lymphoma or Multiple Myeloma Patients
Phase II Study Evaluating the Safety and Efficacy of TXA127 in the Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell Transplant in Patients With Hodgkin Lymphoma, Non-Hodgkin Lymphoma or Multiple Myeloma Undergoing Limited Reinfusion of CD34+ Cells
Status: Enrolling
Updated:  12/31/1969
486
mi
from 43215
Bronx, NY
Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell Transplant (PBSC) in Hodgkin, Non-Hodgkin Lymphoma or Multiple Myeloma Patients
Phase II Study Evaluating the Safety and Efficacy of TXA127 in the Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell Transplant in Patients With Hodgkin Lymphoma, Non-Hodgkin Lymphoma or Multiple Myeloma Undergoing Limited Reinfusion of CD34+ Cells
Status: Enrolling
Updated: 12/31/1969
Montefiori Medical Center
486
mi
from 43215
Bronx, NY
Click here to add this to my saved trials
Everolimus, Bortezomib and/or Rituximab in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia
Phase I/II Study of Combination Everolimus (RAD001), and Rituximab (Rituxan), OR Everolimus, Bortezomib (Velcade, PS-341), and Rituximab in Patients With Relapsed and/or Relapsed/Refractory Waldenstrom's Macroglobulinemia
Status: Enrolling
Updated:  12/31/1969
1161
mi
from 43215
Denver, CO
Everolimus, Bortezomib and/or Rituximab in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia
Phase I/II Study of Combination Everolimus (RAD001), and Rituximab (Rituxan), OR Everolimus, Bortezomib (Velcade, PS-341), and Rituximab in Patients With Relapsed and/or Relapsed/Refractory Waldenstrom's Macroglobulinemia
Status: Enrolling
Updated: 12/31/1969
Colorado Blood Cancer Institute
1161
mi
from 43215
Denver, CO
Click here to add this to my saved trials
Everolimus, Bortezomib and/or Rituximab in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia
Phase I/II Study of Combination Everolimus (RAD001), and Rituximab (Rituxan), OR Everolimus, Bortezomib (Velcade, PS-341), and Rituximab in Patients With Relapsed and/or Relapsed/Refractory Waldenstrom's Macroglobulinemia
Status: Enrolling
Updated:  12/31/1969
643
mi
from 43215
Boston, MA
Everolimus, Bortezomib and/or Rituximab in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia
Phase I/II Study of Combination Everolimus (RAD001), and Rituximab (Rituxan), OR Everolimus, Bortezomib (Velcade, PS-341), and Rituximab in Patients With Relapsed and/or Relapsed/Refractory Waldenstrom's Macroglobulinemia
Status: Enrolling
Updated: 12/31/1969
Dana-Farber Cancer Institute
643
mi
from 43215
Boston, MA
Click here to add this to my saved trials
Everolimus, Bortezomib and/or Rituximab in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia
Phase I/II Study of Combination Everolimus (RAD001), and Rituximab (Rituxan), OR Everolimus, Bortezomib (Velcade, PS-341), and Rituximab in Patients With Relapsed and/or Relapsed/Refractory Waldenstrom's Macroglobulinemia
Status: Enrolling
Updated:  12/31/1969
643
mi
from 43215
Boston, MA
Everolimus, Bortezomib and/or Rituximab in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia
Phase I/II Study of Combination Everolimus (RAD001), and Rituximab (Rituxan), OR Everolimus, Bortezomib (Velcade, PS-341), and Rituximab in Patients With Relapsed and/or Relapsed/Refractory Waldenstrom's Macroglobulinemia
Status: Enrolling
Updated: 12/31/1969
Milford Hospital
643
mi
from 43215
Boston, MA
Click here to add this to my saved trials
An Open-label Safety Study of S-888711
An Open-label Safety Study of S-888711 in Adult Subjects With Relapsed Persistent or Chronic Immune Thrombocytopenia With or Without Prior Splenectomy
Status: Enrolling
Updated:  12/31/1969
797
mi
from 43215
Metairie, LA
An Open-label Safety Study of S-888711
An Open-label Safety Study of S-888711 in Adult Subjects With Relapsed Persistent or Chronic Immune Thrombocytopenia With or Without Prior Splenectomy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
797
mi
from 43215
Metairie, LA
Click here to add this to my saved trials
An Open-label Safety Study of S-888711
An Open-label Safety Study of S-888711 in Adult Subjects With Relapsed Persistent or Chronic Immune Thrombocytopenia With or Without Prior Splenectomy
Status: Enrolling
Updated:  12/31/1969
502
mi
from 43215
Jefferson City, MO
An Open-label Safety Study of S-888711
An Open-label Safety Study of S-888711 in Adult Subjects With Relapsed Persistent or Chronic Immune Thrombocytopenia With or Without Prior Splenectomy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
502
mi
from 43215
Jefferson City, MO
Click here to add this to my saved trials
An Open-label Safety Study of S-888711
An Open-label Safety Study of S-888711 in Adult Subjects With Relapsed Persistent or Chronic Immune Thrombocytopenia With or Without Prior Splenectomy
Status: Enrolling
Updated:  12/31/1969
1962
mi
from 43215
Anaheim, CA
An Open-label Safety Study of S-888711
An Open-label Safety Study of S-888711 in Adult Subjects With Relapsed Persistent or Chronic Immune Thrombocytopenia With or Without Prior Splenectomy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1962
mi
from 43215
Anaheim, CA
Click here to add this to my saved trials
An Open-label Safety Study of S-888711
An Open-label Safety Study of S-888711 in Adult Subjects With Relapsed Persistent or Chronic Immune Thrombocytopenia With or Without Prior Splenectomy
Status: Enrolling
Updated:  12/31/1969
1972
mi
from 43215
Los Angeles, CA
An Open-label Safety Study of S-888711
An Open-label Safety Study of S-888711 in Adult Subjects With Relapsed Persistent or Chronic Immune Thrombocytopenia With or Without Prior Splenectomy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1972
mi
from 43215
Los Angeles, CA
Click here to add this to my saved trials
An Open-label Safety Study of S-888711
An Open-label Safety Study of S-888711 in Adult Subjects With Relapsed Persistent or Chronic Immune Thrombocytopenia With or Without Prior Splenectomy
Status: Enrolling
Updated:  12/31/1969
328
mi
from 43215
Washington,
An Open-label Safety Study of S-888711
An Open-label Safety Study of S-888711 in Adult Subjects With Relapsed Persistent or Chronic Immune Thrombocytopenia With or Without Prior Splenectomy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
328
mi
from 43215
Washington,
Click here to add this to my saved trials
An Open-label Safety Study of S-888711
An Open-label Safety Study of S-888711 in Adult Subjects With Relapsed Persistent or Chronic Immune Thrombocytopenia With or Without Prior Splenectomy
Status: Enrolling
Updated:  12/31/1969
943
mi
from 43215
Boynton Beach, FL
An Open-label Safety Study of S-888711
An Open-label Safety Study of S-888711 in Adult Subjects With Relapsed Persistent or Chronic Immune Thrombocytopenia With or Without Prior Splenectomy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
943
mi
from 43215
Boynton Beach, FL
Click here to add this to my saved trials
An Open-label Safety Study of S-888711
An Open-label Safety Study of S-888711 in Adult Subjects With Relapsed Persistent or Chronic Immune Thrombocytopenia With or Without Prior Splenectomy
Status: Enrolling
Updated:  12/31/1969
668
mi
from 43215
Jacksonville, FL
An Open-label Safety Study of S-888711
An Open-label Safety Study of S-888711 in Adult Subjects With Relapsed Persistent or Chronic Immune Thrombocytopenia With or Without Prior Splenectomy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
668
mi
from 43215
Jacksonville, FL
Click here to add this to my saved trials
An Open-label Safety Study of S-888711
An Open-label Safety Study of S-888711 in Adult Subjects With Relapsed Persistent or Chronic Immune Thrombocytopenia With or Without Prior Splenectomy
Status: Enrolling
Updated:  12/31/1969
436
mi
from 43215
Atlanta, GA
An Open-label Safety Study of S-888711
An Open-label Safety Study of S-888711 in Adult Subjects With Relapsed Persistent or Chronic Immune Thrombocytopenia With or Without Prior Splenectomy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
436
mi
from 43215
Atlanta, GA
Click here to add this to my saved trials
An Open-label Safety Study of S-888711
An Open-label Safety Study of S-888711 in Adult Subjects With Relapsed Persistent or Chronic Immune Thrombocytopenia With or Without Prior Splenectomy
Status: Enrolling
Updated:  12/31/1969
448
mi
from 43215
Riverdale, GA
An Open-label Safety Study of S-888711
An Open-label Safety Study of S-888711 in Adult Subjects With Relapsed Persistent or Chronic Immune Thrombocytopenia With or Without Prior Splenectomy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
448
mi
from 43215
Riverdale, GA
Click here to add this to my saved trials
An Open-label Safety Study of S-888711
An Open-label Safety Study of S-888711 in Adult Subjects With Relapsed Persistent or Chronic Immune Thrombocytopenia With or Without Prior Splenectomy
Status: Enrolling
Updated:  12/31/1969
323
mi
from 43215
Bethesda, MD
An Open-label Safety Study of S-888711
An Open-label Safety Study of S-888711 in Adult Subjects With Relapsed Persistent or Chronic Immune Thrombocytopenia With or Without Prior Splenectomy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
323
mi
from 43215
Bethesda, MD
Click here to add this to my saved trials
An Open-label Safety Study of S-888711
An Open-label Safety Study of S-888711 in Adult Subjects With Relapsed Persistent or Chronic Immune Thrombocytopenia With or Without Prior Splenectomy
Status: Enrolling
Updated:  12/31/1969
643
mi
from 43215
Boston, MA
An Open-label Safety Study of S-888711
An Open-label Safety Study of S-888711 in Adult Subjects With Relapsed Persistent or Chronic Immune Thrombocytopenia With or Without Prior Splenectomy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
643
mi
from 43215
Boston, MA
Click here to add this to my saved trials
An Open-label Safety Study of S-888711
An Open-label Safety Study of S-888711 in Adult Subjects With Relapsed Persistent or Chronic Immune Thrombocytopenia With or Without Prior Splenectomy
Status: Enrolling
Updated:  12/31/1969
618
mi
from 43215
Kansas City, MO
An Open-label Safety Study of S-888711
An Open-label Safety Study of S-888711 in Adult Subjects With Relapsed Persistent or Chronic Immune Thrombocytopenia With or Without Prior Splenectomy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
618
mi
from 43215
Kansas City, MO
Click here to add this to my saved trials
An Open-label Safety Study of S-888711
An Open-label Safety Study of S-888711 in Adult Subjects With Relapsed Persistent or Chronic Immune Thrombocytopenia With or Without Prior Splenectomy
Status: Enrolling
Updated:  12/31/1969
453
mi
from 43215
New Brunswick, NJ
An Open-label Safety Study of S-888711
An Open-label Safety Study of S-888711 in Adult Subjects With Relapsed Persistent or Chronic Immune Thrombocytopenia With or Without Prior Splenectomy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
453
mi
from 43215
New Brunswick, NJ
Click here to add this to my saved trials
An Open-label Safety Study of S-888711
An Open-label Safety Study of S-888711 in Adult Subjects With Relapsed Persistent or Chronic Immune Thrombocytopenia With or Without Prior Splenectomy
Status: Enrolling
Updated:  12/31/1969
481
mi
from 43215
New York, NY
An Open-label Safety Study of S-888711
An Open-label Safety Study of S-888711 in Adult Subjects With Relapsed Persistent or Chronic Immune Thrombocytopenia With or Without Prior Splenectomy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
481
mi
from 43215
New York, NY
Click here to add this to my saved trials
An Open-label Safety Study of S-888711
An Open-label Safety Study of S-888711 in Adult Subjects With Relapsed Persistent or Chronic Immune Thrombocytopenia With or Without Prior Splenectomy
Status: Enrolling
Updated:  12/31/1969
127
mi
from 43215
Cleveland, OH
An Open-label Safety Study of S-888711
An Open-label Safety Study of S-888711 in Adult Subjects With Relapsed Persistent or Chronic Immune Thrombocytopenia With or Without Prior Splenectomy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
127
mi
from 43215
Cleveland, OH
Click here to add this to my saved trials
An Open-label Safety Study of S-888711
An Open-label Safety Study of S-888711 in Adult Subjects With Relapsed Persistent or Chronic Immune Thrombocytopenia With or Without Prior Splenectomy
Status: Enrolling
Updated:  12/31/1969
1144
mi
from 43215
San Antonio, TX
An Open-label Safety Study of S-888711
An Open-label Safety Study of S-888711 in Adult Subjects With Relapsed Persistent or Chronic Immune Thrombocytopenia With or Without Prior Splenectomy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1144
mi
from 43215
San Antonio, TX
Click here to add this to my saved trials
An Open-label Safety Study of S-888711
An Open-label Safety Study of S-888711 in Adult Subjects With Relapsed Persistent or Chronic Immune Thrombocytopenia With or Without Prior Splenectomy
Status: Enrolling
Updated:  12/31/1969
1513
mi
from 43215
Salt Lake City, UT
An Open-label Safety Study of S-888711
An Open-label Safety Study of S-888711 in Adult Subjects With Relapsed Persistent or Chronic Immune Thrombocytopenia With or Without Prior Splenectomy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1513
mi
from 43215
Salt Lake City, UT
Click here to add this to my saved trials
An Open-label Safety Study of S-888711
An Open-label Safety Study of S-888711 in Adult Subjects With Relapsed Persistent or Chronic Immune Thrombocytopenia With or Without Prior Splenectomy
Status: Enrolling
Updated:  12/31/1969
2005
mi
from 43215
Seattle, WA
An Open-label Safety Study of S-888711
An Open-label Safety Study of S-888711 in Adult Subjects With Relapsed Persistent or Chronic Immune Thrombocytopenia With or Without Prior Splenectomy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2005
mi
from 43215
Seattle, WA
Click here to add this to my saved trials
AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma
Phase I Study of AR-42 in Relapsed Myeloma, Chronic Lymphocytic Leukemia, and Lymphoma
Status: Enrolling
Updated:  12/31/1969
2
mi
from 43215
Columbus, OH
AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma
Phase I Study of AR-42 in Relapsed Myeloma, Chronic Lymphocytic Leukemia, and Lymphoma
Status: Enrolling
Updated: 12/31/1969
The Ohio State University James Cancer Hospital
2
mi
from 43215
Columbus, OH
Click here to add this to my saved trials
Busulfan, Melphalan, Fludarabine and T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Followed by Post Transplantation Donor Lymphocyte Infusions
A Trial of Busulfan, Melphalan, Fludarabine and T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Followed by Post Transplantation Donor Lymphocyte Infusions for Patients With Relapsed or High-Risk Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
480
mi
from 43215
New York, NY
Busulfan, Melphalan, Fludarabine and T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Followed by Post Transplantation Donor Lymphocyte Infusions
A Trial of Busulfan, Melphalan, Fludarabine and T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Followed by Post Transplantation Donor Lymphocyte Infusions for Patients With Relapsed or High-Risk Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering Cancer Center
480
mi
from 43215
New York, NY
Click here to add this to my saved trials
Lenalidomide and Prednisone in Low and Int-1 Myelodysplastic Syndrome (MDS) Non 5q MDS
A Phase II Clinical Trial of Lenalidomide and Prednisone in Low and Intermediate-1 IPSS Risk, Non-del (5q) MDS Patients
Status: Enrolling
Updated:  12/31/1969
714
mi
from 43215
Gainesville, FL
Lenalidomide and Prednisone in Low and Int-1 Myelodysplastic Syndrome (MDS) Non 5q MDS
A Phase II Clinical Trial of Lenalidomide and Prednisone in Low and Intermediate-1 IPSS Risk, Non-del (5q) MDS Patients
Status: Enrolling
Updated: 12/31/1969
University of Florida Shands Cancer Center
714
mi
from 43215
Gainesville, FL
Click here to add this to my saved trials
Lenalidomide and Prednisone in Low and Int-1 Myelodysplastic Syndrome (MDS) Non 5q MDS
A Phase II Clinical Trial of Lenalidomide and Prednisone in Low and Intermediate-1 IPSS Risk, Non-del (5q) MDS Patients
Status: Enrolling
Updated:  12/31/1969
823
mi
from 43215
Tampa, FL
Lenalidomide and Prednisone in Low and Int-1 Myelodysplastic Syndrome (MDS) Non 5q MDS
A Phase II Clinical Trial of Lenalidomide and Prednisone in Low and Intermediate-1 IPSS Risk, Non-del (5q) MDS Patients
Status: Enrolling
Updated: 12/31/1969
H. Lee Moffitt Cancer Center & Research Institute
823
mi
from 43215
Tampa, FL
Click here to add this to my saved trials
Specimen Collection for Agricultural Health Study Cohort Pesticide Exposure Study
Study of Biomarkers of Exposure and Effects in Agriculture
Status: Enrolling
Updated:  12/31/1969
461
mi
from 43215
Iowa City, IA
Specimen Collection for Agricultural Health Study Cohort Pesticide Exposure Study
Study of Biomarkers of Exposure and Effects in Agriculture
Status: Enrolling
Updated: 12/31/1969
University of Iowa
461
mi
from 43215
Iowa City, IA
Click here to add this to my saved trials
Veliparib and Temozolomide in Treating Patients With Acute Leukemia
A Phase I Study of the PARP Inhibitor ABT-888 in Combination With Temozolomide in Acute Leukemias
Status: Enrolling
Updated:  12/31/1969
343
mi
from 43215
Baltimore, MD
Veliparib and Temozolomide in Treating Patients With Acute Leukemia
A Phase I Study of the PARP Inhibitor ABT-888 in Combination With Temozolomide in Acute Leukemias
Status: Enrolling
Updated: 12/31/1969
University of Maryland Greenebaum Cancer Center
343
mi
from 43215
Baltimore, MD
Click here to add this to my saved trials
Veliparib and Temozolomide in Treating Patients With Acute Leukemia
A Phase I Study of the PARP Inhibitor ABT-888 in Combination With Temozolomide in Acute Leukemias
Status: Enrolling
Updated:  12/31/1969
274
mi
from 43215
Chicago, IL
Veliparib and Temozolomide in Treating Patients With Acute Leukemia
A Phase I Study of the PARP Inhibitor ABT-888 in Combination With Temozolomide in Acute Leukemias
Status: Enrolling
Updated: 12/31/1969
University of Chicago Comprehensive Cancer Center
274
mi
from 43215
Chicago, IL
Click here to add this to my saved trials
Veliparib and Temozolomide in Treating Patients With Acute Leukemia
A Phase I Study of the PARP Inhibitor ABT-888 in Combination With Temozolomide in Acute Leukemias
Status: Enrolling
Updated:  12/31/1969
345
mi
from 43215
Baltimore, MD
Veliparib and Temozolomide in Treating Patients With Acute Leukemia
A Phase I Study of the PARP Inhibitor ABT-888 in Combination With Temozolomide in Acute Leukemias
Status: Enrolling
Updated: 12/31/1969
Johns Hopkins University-Sidney Kimmel Cancer Center
345
mi
from 43215
Baltimore, MD
Click here to add this to my saved trials
A Trial of Photodynamic Therapy With HPPH for Treatment of Dysplasia, Carcinoma in Situ and T1 Carcinoma of the Oral Cavity and/or Oropharynx
A Phase la Trial of Photodynamic Therapy With HPPH (2-1 (Hexyloxyethyl)-2-devinylpyropheophorbide-a) for Treatment of Dysplasia, Carcinoma in Situ and T1 Carcinoma of the Oral Cavity and/or Oropharynx.
Status: Enrolling
Updated:  12/31/1969
295
mi
from 43215
Buffalo, NY
A Trial of Photodynamic Therapy With HPPH for Treatment of Dysplasia, Carcinoma in Situ and T1 Carcinoma of the Oral Cavity and/or Oropharynx
A Phase la Trial of Photodynamic Therapy With HPPH (2-1 (Hexyloxyethyl)-2-devinylpyropheophorbide-a) for Treatment of Dysplasia, Carcinoma in Situ and T1 Carcinoma of the Oral Cavity and/or Oropharynx.
Status: Enrolling
Updated: 12/31/1969
Roswell Park Cancer Institute
295
mi
from 43215
Buffalo, NY
Click here to add this to my saved trials
Lenalidomide and High Dose Melphalan Followed by Autologous Stem Cell Transplant in Multiple Myeloma
Phase I/II Study of Oral Lenalidomide and High Dose Melphalan Supported by Autologous Peripheral Blood Stem Cell Infusion for Patients With Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
166
mi
from 43215
Indianapolis, IN
Lenalidomide and High Dose Melphalan Followed by Autologous Stem Cell Transplant in Multiple Myeloma
Phase I/II Study of Oral Lenalidomide and High Dose Melphalan Supported by Autologous Peripheral Blood Stem Cell Infusion for Patients With Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
IU Simon Cancer Center
166
mi
from 43215
Indianapolis, IN
Click here to add this to my saved trials
Interventional Study in Adults With Immune Thrombocytopenia Purpura (ITP) Receiving Romiplostim
A Phase 2 Interventional Single Arm Study Describing Platelet Responses and ITP Remission Rates in Adult Subjects With Immune Thrombocytopenia Purpura Receiving Romiplostim
Status: Enrolling
Updated:  12/31/1969
1962
mi
from 43215
Anaheim, CA
Interventional Study in Adults With Immune Thrombocytopenia Purpura (ITP) Receiving Romiplostim
A Phase 2 Interventional Single Arm Study Describing Platelet Responses and ITP Remission Rates in Adult Subjects With Immune Thrombocytopenia Purpura Receiving Romiplostim
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1962
mi
from 43215
Anaheim, CA
Click here to add this to my saved trials
Interventional Study in Adults With Immune Thrombocytopenia Purpura (ITP) Receiving Romiplostim
A Phase 2 Interventional Single Arm Study Describing Platelet Responses and ITP Remission Rates in Adult Subjects With Immune Thrombocytopenia Purpura Receiving Romiplostim
Status: Enrolling
Updated:  12/31/1969
1959
mi
from 43215
Orange, CA
Interventional Study in Adults With Immune Thrombocytopenia Purpura (ITP) Receiving Romiplostim
A Phase 2 Interventional Single Arm Study Describing Platelet Responses and ITP Remission Rates in Adult Subjects With Immune Thrombocytopenia Purpura Receiving Romiplostim
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1959
mi
from 43215
Orange, CA
Click here to add this to my saved trials
Interventional Study in Adults With Immune Thrombocytopenia Purpura (ITP) Receiving Romiplostim
A Phase 2 Interventional Single Arm Study Describing Platelet Responses and ITP Remission Rates in Adult Subjects With Immune Thrombocytopenia Purpura Receiving Romiplostim
Status: Enrolling
Updated:  12/31/1969
943
mi
from 43215
Boynton Beach, FL
Interventional Study in Adults With Immune Thrombocytopenia Purpura (ITP) Receiving Romiplostim
A Phase 2 Interventional Single Arm Study Describing Platelet Responses and ITP Remission Rates in Adult Subjects With Immune Thrombocytopenia Purpura Receiving Romiplostim
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
943
mi
from 43215
Boynton Beach, FL
Click here to add this to my saved trials
Interventional Study in Adults With Immune Thrombocytopenia Purpura (ITP) Receiving Romiplostim
A Phase 2 Interventional Single Arm Study Describing Platelet Responses and ITP Remission Rates in Adult Subjects With Immune Thrombocytopenia Purpura Receiving Romiplostim
Status: Enrolling
Updated:  12/31/1969
323
mi
from 43215
Bethesda, MD
Interventional Study in Adults With Immune Thrombocytopenia Purpura (ITP) Receiving Romiplostim
A Phase 2 Interventional Single Arm Study Describing Platelet Responses and ITP Remission Rates in Adult Subjects With Immune Thrombocytopenia Purpura Receiving Romiplostim
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
323
mi
from 43215
Bethesda, MD
Click here to add this to my saved trials
Interventional Study in Adults With Immune Thrombocytopenia Purpura (ITP) Receiving Romiplostim
A Phase 2 Interventional Single Arm Study Describing Platelet Responses and ITP Remission Rates in Adult Subjects With Immune Thrombocytopenia Purpura Receiving Romiplostim
Status: Enrolling
Updated:  12/31/1969
304
mi
from 43215
Hickory, NC
Interventional Study in Adults With Immune Thrombocytopenia Purpura (ITP) Receiving Romiplostim
A Phase 2 Interventional Single Arm Study Describing Platelet Responses and ITP Remission Rates in Adult Subjects With Immune Thrombocytopenia Purpura Receiving Romiplostim
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
304
mi
from 43215
Hickory, NC
Click here to add this to my saved trials
Interventional Study in Adults With Immune Thrombocytopenia Purpura (ITP) Receiving Romiplostim
A Phase 2 Interventional Single Arm Study Describing Platelet Responses and ITP Remission Rates in Adult Subjects With Immune Thrombocytopenia Purpura Receiving Romiplostim
Status: Enrolling
Updated:  12/31/1969
416
mi
from 43215
Philadelphia, PA
Interventional Study in Adults With Immune Thrombocytopenia Purpura (ITP) Receiving Romiplostim
A Phase 2 Interventional Single Arm Study Describing Platelet Responses and ITP Remission Rates in Adult Subjects With Immune Thrombocytopenia Purpura Receiving Romiplostim
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
416
mi
from 43215
Philadelphia, PA
Click here to add this to my saved trials
Interventional Study in Adults With Immune Thrombocytopenia Purpura (ITP) Receiving Romiplostim
A Phase 2 Interventional Single Arm Study Describing Platelet Responses and ITP Remission Rates in Adult Subjects With Immune Thrombocytopenia Purpura Receiving Romiplostim
Status: Enrolling
Updated:  12/31/1969
527
mi
from 43215
Charleston, SC
Interventional Study in Adults With Immune Thrombocytopenia Purpura (ITP) Receiving Romiplostim
A Phase 2 Interventional Single Arm Study Describing Platelet Responses and ITP Remission Rates in Adult Subjects With Immune Thrombocytopenia Purpura Receiving Romiplostim
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
527
mi
from 43215
Charleston, SC
Click here to add this to my saved trials